Breaking the Cancer Glycan Code
The attachment of sugars (glycans) to proteins and other cellular scaffolds is a common event in healthy cells. For cancer cells these processes are dysregulated, and cancers express unique glycan structures compared to healthy tissues. Expression of these aberrant sugars shield tumors from immune attack and are markers for poor survival. Glyde is mining the cancer glycome as a rich source of neoantigens for cancer immuno-therapy. Our powerful R&D strategies and technologies are designed to turn this tumor escape mechanism into a critical weakness for a variety of solid tumors and leukemias.
Our Vision
Tumors differ from healthy cells in many ways and cancer glycans are remarkable in this regard. Although these differences can be recognized by a patient’s immune system, cancers evolve ways to evade and suppress this response. Indeed, aberrant glycans play a key role in hiding cancer from the immune system. Targeting this new class of tumor neoantigens and breaking the Cancer Glycan Code will lead to dramatic advances in cancer therapies.
Contact Us
Glyde Bio, Inc.
325 Vassar Street
Cambridge, MA
For more information, please contact us at info@glydebio.com.